Feb 06, 2020
Cellectricon and StressMarq Biosciences collaborate to develop next generation reagents and assays to advance neurodegenerative disease research
Dec 05, 2019
Samus Therapeutics Announces Presentation of PU-AD Phase 1 Data for Alzheimer's Disease at CTAD Congress
Dec 03, 2019
Clene Nanomedicine Announces First Patient Enrolled in the REPAIR-PD Clinical Trial for the Treatment of Parkinson's Disease with the Nanocatalytic Therapeutic, CNM-Au8
Nov 07, 2019
Arkuda Therapeutics Closes $44M Series A Financing to Advance Novel Medicines Targeting Progranulin and Lysosomal Biology to Treat Neurodegenerative Diseases
Nov 04, 2019
T3D Therapeutics Closes $15M Financing to Advance Phase 2 Development of T3D-959 in a New Approach to Treating Alzheimer's Disease.
Oct 23, 2019
ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43
Oct 22, 2019
Rainwater Charitable Foundation Announces Inaugural Winners As Part of World's Largest Prize Program for Brain Research
Oct 21, 2019
When Prions are Personal
Oct 17, 2019
ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau
Oct 08, 2019
ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy
Oct 07, 2019
Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration
Sep 27, 2019
Global Emerging Therapeutics Markets for Neurodegenerative Diseases, 2019: Focus on Novel Targeted Therapeutic Strategies Technologies for Alzheimer's and Parkinson's Diseases
Sep 23, 2019
4D pharma plc: Publication of Data on Neurodegenerative Disease Programmes
Sep 12, 2019
Growth Opportunities in the Neurodegenerative Disorder Therapeutics Market - Global Forecast to 2024
Sep 09, 2019
Axon Announces Positive Results From Phase II ADAMANT Trial for AADvac1 in Alzheimer's Disease
Sep 05, 2019
Emerging Therapeutics for Neurodegenerative Diseases, Part I: Novel Targeted Therapeutic Strategies Technologies for Alzheimer's and Parkinson's Diseases
Aug 27, 2019
ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer's Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board
Aug 14, 2019
Bach Pharma Inc, Developing New Drug, GVT® to Treat Veterans Suffering from Gulf War Illness, and Millions of People Suffering from Neurodegenerative Diseases
Jul 23, 2019
Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer's Disease
Jul 15, 2019
Advances In The Global Search For Blood Markers For Alzheimer's Disease And Other Dementias